An understanding of the molecular pathways involved in insulin secretion is useful in explaining such clinical observations as the ability of GLP-1R agonists to reduce hyperglycaemia with a low likelihood of hypoglycaemia. This evidence concerns the gene INS and Hypoglycemia.